All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
